CGEN
Undervalued by 97.1% based on the discounted cash flow analysis.
Market cap | $138.40 Million |
---|---|
Enterprise Value | $132.71 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-0.16 |
Beta | 3.2 |
Outstanding Shares | 89,538,891 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -9.31 |
---|---|
PEG | 8.24 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | 2.22 |
Enterprise Value to EBIT | 12.55 |
Enterprise Value to Net Income | 82 |
Total Debt to Enterprise | 0.09 |
Debt to Equity | 0.23 |
No data
No data
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...